To directly determine the in vivo role of CDC and ADCC in the antitumoral potential of 92R mAb, we generated subcutaneous xenografts by injection of 1 × 106 CCR9+ cells from the human T-ALL cell line MOLT-4 in NSG mice. The gene discussed is CCR9; the disease is acute lymphoblastic leukemia.